Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Potential Role Of Tigecycline In The Treatment Of Community-Acquired Bacterial Pneumonia, M. L. Townsend, M. W. Pound, R. H. Drew
Potential Role Of Tigecycline In The Treatment Of Community-Acquired Bacterial Pneumonia, M. L. Townsend, M. W. Pound, R. H. Drew
Pharmacy Practice
Tigecycline is a member of the glycylcycline class of antimicrobials, which is structurally similar to the tetracycline class. It demonstrates potent in vitro activity against causative pathogens that are most frequently isolated in patients with community-acquired bacterial pneumonia (CABP), including (but not limited to) Streptococcus pneumoniae (both penicillin-sensitive and -resistant strains), Haemophilus influenzae and Moraxella catarrhalis (including β-lactamase-producing strains), Klebsiella pneumoniae, and ‘atypical organisms’ (namely Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila). Comparative randomized clinical trials to date performed in hospitalized patients receiving tigecycline 100 mg intravenous (IV) × 1 and then 50 mg IV twice daily thereafter have demonstrated …
Tigecycline In The Treatment Of Complicated Intra-Abdominal And Complicated Skin And Skin Structure Infections, M. L. Townsend, M. W. Pound, R. H. Drew
Tigecycline In The Treatment Of Complicated Intra-Abdominal And Complicated Skin And Skin Structure Infections, M. L. Townsend, M. W. Pound, R. H. Drew
Pharmacy Practice
Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents a new option for the treatment of complicated intra-abdominal and complicated skin and skin structure infections. It displays favorable activity in vitro against the most common causative Gram-positive, Gram-negative and anaerobic pathogens. In addition, tigecycline demonstrates activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and organisms (such as Escherichia coli and Klebsiella pneumoniae) producing extended-spectrum beta-lactamases. Tigecycline lacks activity in vitro against Pseudomonas and Proteus spp. In randomized clinical trials, tigecycline administered intravenously twice daily has demonstrated efficacy similar to comparators for a variety …